115:(or Delphi technique). The Rome Foundation process is an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, also known as disorders of gut-brain interaction. The Rome Diagnostic criteria are set forth by the Rome Foundation, an independent, not for profit 501(c)(3) organization.
59:(FGIDs). As a result, there were several key events which ultimately led to the current Rome Classification. In 1962, Chaudhary and Truelove published their study of IBS patients in Oxford, England. This was the first attempt to classify the new field of functional gastrointestinal disorders. Much of what they reported has persisted to the present day.
254:
classification to a symptom-based classification with additional classifications based upon organ regions (i.e. esophageal, gastroduodenal, bowel, biliary, anorectal). The current Rome IV classification is the culmination of the evolution of a series of iterations (Rome I, Rome II, and Rome III) with its inception as Rome I.
253:
The original Rome classification was first published in 1990 and has since been modified with each iteration to develop the subsequent classifications with Rome II, III and IV. Beginning with the original publication in 1990 and leading to Rome I, the classification moved from a physiologically based
93:
The Rome criteria have been evolving from the first set of criteria issued in 1989 (The Rome
Guidelines for IBS) through the Rome Classification System for functional gastrointestinal disorders (1990), or Rome-1, the Rome I Criteria for IBS (1992) and the functional gastrointestinal disorders (1994),
70:
From 1980 to 1994, there were several epidemiological and clinical studies evaluating symptom prevalence and frequency in healthy subjects and IBS patients. Thompson, Drossman, Talley, Whitehead, and Kruis. In 1989, the first consensus-based diagnostic criteria for IBS were established. The following
233:
To address the severity and variability of clinical presentation, a
Multidimensional Clinical Profile (MDCP) system has been created that incorporates the diagnostic criteria with additional clinical, quality of life, psychosocial, and physiological (including biomarker) parameters to more precisely
127:
Over the last 25 years, the Rome organization has sought to legitimize and update the knowledge of functional GI disorders. This has been accomplished by bringing together scientists and clinicians from around the world to classify and critically appraise the science of gastrointestinal function and
196:
By the mid-1990s, the concept of FGID classification and the use of diagnostic criteria was promoted due to the US Food and Drug
Administration (FDA) recommended the use of the IBS criteria for selection into pharmaceutical studies, and the pharmaceutical companies took interest in supporting the
98:
criteria to the consensus. The Rome IV update was published 10 years later in May 2016. This covers epidemiology, pathophysiology, psychosocial and clinical features, and diagnostic evaluation and treatment recommendations for 33 adult and 17 pediatric functional gastrointestinal disorders.
968:
Drossman DA. The Rome IV Committees, editor. Functional
Gastrointestinal Disorders and the Rome IV process. In: Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE, editors. Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction. I. Raleigh, NC: The Rome
123:
The Rome
Foundation, incorporated in 1996 and based in Raleigh, North Carolina, is an independent not for profit 501(c) 3 organization. The foundation provides support for activities which foster clinical research, data and educational information which aid in the diagnosis and treatment of
1030:
Drossman DA. The Rome IV Committees, editor. Functional
Gastrointestinal Disorders and the Rome IV process. In: Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE, editors. Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction.I. Raleigh, NC: The Rome
82:
In 1993, a validated questionnaire of all the diagnostic criteria was created and was then applied in a national survey, the US Householder Survey: the first national epidemiological database on the prevalence, demographic factors, and health care seeking features of people with FGIDs.
214:
After publication of Rome III in 2006, the Rome
Foundation was well recognized as the authoritative body developing diagnostic criteria for research and also for providing education about the FGIDs. Rome IV tried to address the limitations of a symptom-based criteria in several ways:
131:
The goals of the Rome
Foundation are to promote global recognition and legitimization of FGIDs, advance the scientific understanding of their pathophysiology, optimize clinical management for these patients and develop and provide educational resources to accomplish these goals.
239:
To help clinicians be better trained in the diagnostic algorithms and the MDCP, the Rome
Foundation is developing an interactive, intelligent software platform that will help clinicians make real-time treatment decisions using the diagnostic algorithms and MDCP knowledge
205:
After publication of Rome II, the number of studies published using the Rome criteria in clinical trials grew tremendously over the next 15 years. Rome III differed from Rome I and II by the use of more evidence-based rather than consensus-based data.
66:
and colleagues in
Bristol. This characterized IBS-D (IBS with predominant diarrhea), but importantly, a cluster of symptoms which were characteristic for this disorder. This ultimately became the basis for Rome's symptom-based criteria for IBS.
128:
dysfunction. This knowledge permits clinical scientists to make recommendations for diagnosis and treatment that can be applied in research and clinical practice. The mission is to improve the lives of people with these disorders.
197:
efforts of the Rome Foundation to improve the understanding, diagnosis, and treatment of FGIDs and to also apply the use of these criteria in their pharmaceutical studies. In Rome II, the pediatric population of FGIDs was added.
244:
In Rome IV, the classification moved from a physiologically based classification to a symptom-based classification. The classifications were based upon organ regions (i.e. esophageal, gastroduodenal, bowel, biliary, anorectal).
74:
From 1991 to 1993, several working teams (esophagus, gastroduodenal, bowel, biliary, anorectal) published symptom-based criteria and clinical features of the functional GI disorders within these anatomic domains in
736:
Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982;83:529–534.
257:
The Rome criteria are a set of criteria used by clinicians to classify a diagnosis of a patient with an FGID (disorder of gut-brain interaction). These Rome criteria are updated every 6–10 years.
146:
Using the Delphi method, the Rome Foundation and its board of directors, chairs and co-chairs of the ROME IV committees developed the current definition for disorders of gut-brain interaction.
853:
Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569–1580.
763:
Kruis W, Thieme CH, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1–7.
869:
Drossman DA, Richter JE, Talley NJ, et al. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean (VA): Degnon Associates, 1994.
745:
Sandler RS, Drossman DA, Nathan HP, et al. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology 1984;87:314–318.
687:
Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962;31:307–322.
94:
the Rome II Criteria for IBS (1999) and the functional gastrointestinal disorders (1999) to the Rome III Criteria (2006). "Rome II" and "Rome III" incorporated
808:
Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145–160
844:
Talley NJ, Nyren O, Drossman DA, et al. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993;4:189–211
1049:
Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean (VA): Degnon Associates, 2006.
1040:
Drossman DA, Corazziari E, Talley NJ, et al., eds. Rome II: the functional gastrointestinal disorders. 2nd ed. McLean (VA): Degnon Associates, 2000.
826:
Corazziari E, Funch-Jensen P, Hogan WJ, et al. Working team report: functional disorders of the biliary tract. Gastroenterol Int 1993;6:129–144.
188:
In 1994, Rome I was published as The Functional Gastrointestinal Disorders:Diagnosis, Pathophysiology, and Treatment—A Multinational Consensus.
1116:
669:
141:
56:
28:
817:
Thompson WG, Creed F, Drossman DA, et al. Functional bowel disorders and chronic functional abdominal pain. Gastroenterol Int 1992;5:75–91
790:
Drossman DA, Thompson WG, Talley NJ, et al. Identification of subgroups of functional bowel disorders. Gastroenterol Int 1990;3:159–172.
781:
Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: Guidelines for the diagnosis. Gastroenterol Int 1989;2:92–95.
596:
358:
754:
Talley NJ, Phillips SF, Melton LJ, et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989;111:671–674
1005:
423:
696:
Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653–654.
219:
Some criteria have been simplified and cases not meeting criteria for research can still be identified and treated.
835:
Whitehead WE, Devroede G, Habib FI, et al. Functional disorders of the anorectum. Gastroenterol Int 1992;5:92–108.
727:
Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980;79:283–288.
222:
Global education on FGIDs help to understand and characterize the cross-cultural differences in symptom reporting.
1111:
156:
108:
380:
351:
88:
The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment – A Multinational Consensus
718:
Torsoli A, Corazziari E. The WTR's, the Delphic Oracle and the Roman Conclaves Gastroenterol Int 1991;4:44–45.
44:
772:
Drossman DA. Diagnosis of the irritable bowel syndrome: A simple solution? Gastroenterology 1984;87:224–225
519:
171:
86:
In 1994, FGIDs were categorized into anatomical domains and resulted in a book now recognized as Rome I –
1058:
879:
Drossman DA, Hasler WL (2016). "Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction".
799:
Richter JE, Baldi F, Clouse RE, et al. Functional oesophageal disorders. Gastroenterol Int 1992;5:3–17
603:
308:
276:
32:
367:
620:
486:
919:"Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV"
1078:
938:
896:
463:
1070:
930:
888:
505:
289:
228:
Creation of diagnostic algorithms for a functional GI disorder diagnosis or other diagnosis
657:
436:
165:
63:
40:
1017:
1006:
https://theromefoundation.org/wp-content/uploads/Meet-The-Rome-Foundation-2017-web.pdf
136:
Definition of functional gastrointestinal disorders/disorders of gut-brain interaction
1105:
112:
543:
401:
1074:
934:
892:
495:
456:
918:
588:
270:
149:
A group of disorders classified by GI symptoms related to any combination of:
95:
552:
295:
24:
1082:
942:
900:
472:
413:
407:
341:
322:
35:
and rumination syndrome. The Rome diagnostic criteria are set forth by
260:
The current Rome IV classification, published in 2016, is as follows:
337:
282:
23:
are an international effort to create scientific data to help in the
1096:
984:
442:
D2. Narcotic bowel syndrome (NBS)/ Opioid-induced GI hyperalgesia
62:
Subsequently, in 1978 came the "Manning Criteria" developed by
107:
The Rome criteria are achieved and finally issued through a
71:
year, a classification system for FGIDs was established.
430:
D. Centrally Mediated Disorders of Gastrointestinal Pain
234:
create an individualized treatment plan for the patient.
562:
H. Childhood Functional GI Disorders: Child/Adolescent
528:
G. Childhood Functional GI Disorders: Neonate/Toddler
55:
Several systematic approaches attempted to classify
16:Diagnostic criteria for gastrointestinal disorders
1004:"Meet the Rome Foundation," 2017. Retrieved from
912:
910:
573:H1b. Functional nausea and functional vomiting
447:E. Gallbladder and Sphincter of Oddi disorders
567:H1. Functional nausea and vomiting disorders
8:
347:B3a. Chronic nausea vomiting syndrome (CNVS)
501:F2b. Unspecified functional anorectal pain
865:
863:
861:
859:
419:C5. Unspecified functional bowel disorder
386:IBS with predominant constipation (IBS-C)
313:B1a. Postprandial distress syndrome (PDS)
225:Provide translations into other languages
1000:
998:
979:
977:
975:
964:
962:
960:
958:
956:
954:
952:
714:
712:
710:
708:
706:
704:
702:
680:
124:functional gastrointestinal disorders.
670:Functional gastrointestinal disorders
515:F3a. Inadequate defecatory propulsion
389:IBS with predominant diarrhea (IBS-D)
57:functional gastrointestinal disorders
29:functional gastrointestinal disorders
7:
636:H3b. Nonretentive fecal incontinence
630:H3. Functional defecation disorders
625:H2d. Functional abdominal pain ‒ NOS
608:H2a1. Postprandial distress syndrome
512:F3. Functional defecation disorders
328:B2a. Excessive supragastric belching
142:Functional gastrointestinal disorder
31:, such as irritable bowel syndrome,
616:H2b. Irritable bowel syndrome (IBS)
570:H1a. Cyclic vomiting syndrome (CVS)
392:IBS with mixed bowel habits (IBS-M)
316:B1b. Epigastric pain syndrome (EPS)
161:Altered mucosal and immune function
539:G3. Cyclic vomiting syndrome (CVS)
14:
359:Cannabinoid hyperemesis syndrome
43:501(c)(3) organization based in
331:B2b. Excessive gastric belching
249:Rome IV criteria/classification
611:H2a2. Epigastric pain syndrome
491:F2. Functional anorectal pain
77:Gastroenterology International
21:Rome process and Rome criteria
1:
1075:10.1053/j.gastro.2006.03.011
1018:"Presentations & Videos"
935:10.1053/j.gastro.2016.02.032
893:10.1053/j.gastro.2016.03.035
633:H3a. Functional constipation
1117:Diagnostic gastroenterology
969:Foundation; 2016. pp. 1–32.
557:G7. Functional constipation
424:Opioid-induced constipation
302:B. Gastroduodenal Disorders
1133:
1031:Foundation; 2016. pp 1–32.
475:sphincter of Oddi disorder
179:Evolution of Rome criteria
139:
597:Functional abdominal pain
579:H1b2. Functional vomiting
412:C4. Functional abdominal
157:Visceral hypersensitivity
584:H1c. Rumination syndrome
533:G1. Infant regurgitation
462:E1b. Functional biliary
395:IBS unclassified (IBS-U)
381:Irritable bowel syndrome
352:Cyclic vomiting syndrome
576:H1b1. Functional nausea
548:G5. Functional diarrhea
536:G2. Rumination syndrome
435:D1. Centrally mediated
264:A. Esophageal Disorders
45:Raleigh, North Carolina
676:References and sources
520:Dyssynergic defecation
480:F. Anorectal Disorders
172:central nervous system
989:theromefoundation.org
1057:Thompson WG (2006).
917:Drossman DA (2016).
604:Functional dyspepsia
309:Functional dyspepsia
277:Functional heartburn
153:Motility disturbance
33:functional dyspepsia
1097:The Rome Foundation
368:Rumination syndrome
119:The Rome Foundation
1059:"The Road to Rome"
621:Abdominal migraine
487:Fecal incontinence
374:C. Bowel Disorders
109:consensual process
464:sphincter of Oddi
452:E1. Biliary pain
47:, United States.
27:and treatment of
1124:
1112:Gastroenterology
1086:
1069:(5): 1552–1556.
1063:Gastroenterology
1050:
1047:
1041:
1038:
1032:
1028:
1022:
1021:
1014:
1008:
1002:
993:
992:
981:
970:
966:
947:
946:
929:(6): 1262–1279.
923:Gastroenterology
914:
905:
904:
881:Gastroenterology
876:
870:
867:
854:
851:
845:
842:
836:
833:
827:
824:
818:
815:
809:
806:
800:
797:
791:
788:
782:
779:
773:
770:
764:
761:
755:
752:
746:
743:
737:
734:
728:
725:
719:
716:
697:
694:
688:
685:
648:Douglas Drossman
506:Proctalgia fugax
455:E1a. Functional
285:hypersensitivity
174:(CNS) processing
1132:
1131:
1127:
1126:
1125:
1123:
1122:
1121:
1102:
1101:
1093:
1056:
1053:
1048:
1044:
1039:
1035:
1029:
1025:
1016:
1015:
1011:
1003:
996:
983:
982:
973:
967:
950:
916:
915:
908:
878:
877:
873:
868:
857:
852:
848:
843:
839:
834:
830:
825:
821:
816:
812:
807:
803:
798:
794:
789:
785:
780:
776:
771:
767:
762:
758:
753:
749:
744:
740:
735:
731:
726:
722:
717:
700:
695:
691:
686:
682:
678:
666:
658:Nicholas Talley
645:
471:E2. Functional
439:syndrome (CAPS)
406:C3. Functional
400:C2. Functional
294:A5. Functional
269:A1. Functional
251:
212:
203:
194:
186:
181:
144:
138:
121:
105:
53:
37:Rome Foundation
17:
12:
11:
5:
1130:
1128:
1120:
1119:
1114:
1104:
1103:
1100:
1099:
1092:
1091:External links
1089:
1088:
1087:
1052:
1051:
1042:
1033:
1023:
1009:
994:
971:
948:
906:
887:(6): 1257–61.
871:
855:
846:
837:
828:
819:
810:
801:
792:
783:
774:
765:
756:
747:
738:
729:
720:
698:
689:
679:
677:
674:
673:
672:
665:
662:
661:
660:
655:
652:
649:
644:
643:Notable People
641:
640:
639:
638:
637:
634:
628:
627:
626:
623:
617:
614:
613:
612:
609:
593:
592:
591:
585:
582:
581:
580:
577:
571:
559:
558:
555:
549:
546:
540:
537:
534:
525:
524:
523:
522:
516:
510:
509:
508:
502:
499:
489:
477:
476:
469:
468:
467:
460:
444:
443:
440:
437:abdominal pain
427:
426:
420:
417:
410:
404:
398:
397:
396:
393:
390:
387:
371:
370:
364:
363:
362:
355:
348:
334:
333:
332:
329:
319:
318:
317:
314:
299:
298:
292:
286:
279:
273:
250:
247:
242:
241:
236:
235:
230:
229:
226:
223:
220:
211:
208:
202:
199:
193:
190:
185:
182:
180:
177:
176:
175:
168:
166:gut microbiota
162:
159:
154:
137:
134:
120:
117:
104:
101:
64:Kenneth Heaton
52:
49:
41:not for profit
15:
13:
10:
9:
6:
4:
3:
2:
1129:
1118:
1115:
1113:
1110:
1109:
1107:
1098:
1095:
1094:
1090:
1084:
1080:
1076:
1072:
1068:
1064:
1060:
1055:
1054:
1046:
1043:
1037:
1034:
1027:
1024:
1019:
1013:
1010:
1007:
1001:
999:
995:
990:
986:
980:
978:
976:
972:
965:
963:
961:
959:
957:
955:
953:
949:
944:
940:
936:
932:
928:
924:
920:
913:
911:
907:
902:
898:
894:
890:
886:
882:
875:
872:
866:
864:
862:
860:
856:
850:
847:
841:
838:
832:
829:
823:
820:
814:
811:
805:
802:
796:
793:
787:
784:
778:
775:
769:
766:
760:
757:
751:
748:
742:
739:
733:
730:
724:
721:
715:
713:
711:
709:
707:
705:
703:
699:
693:
690:
684:
681:
675:
671:
668:
667:
663:
659:
656:
654:Robin Spiller
653:
650:
647:
646:
642:
635:
632:
631:
629:
624:
622:
618:
615:
610:
607:
606:
605:
601:
600:
598:
594:
590:
586:
583:
578:
575:
574:
572:
569:
568:
566:
565:
564:
563:
556:
554:
550:
547:
545:
541:
538:
535:
532:
531:
530:
529:
521:
517:
514:
513:
511:
507:
503:
500:
497:
493:
492:
490:
488:
484:
483:
482:
481:
474:
470:
465:
461:
458:
454:
453:
451:
450:
449:
448:
441:
438:
434:
433:
432:
431:
425:
421:
418:
415:
411:
409:
405:
403:
399:
394:
391:
388:
385:
384:
382:
378:
377:
376:
375:
369:
365:
360:
356:
353:
349:
346:
345:
343:
339:
335:
330:
327:
326:
324:
320:
315:
312:
311:
310:
306:
305:
304:
303:
297:
293:
291:
287:
284:
280:
278:
274:
272:
268:
267:
266:
265:
261:
258:
255:
248:
246:
238:
237:
232:
231:
227:
224:
221:
218:
217:
216:
209:
207:
200:
198:
191:
189:
183:
178:
173:
169:
167:
163:
160:
158:
155:
152:
151:
150:
147:
143:
135:
133:
129:
125:
118:
116:
114:
113:Delphi method
110:
102:
100:
97:
91:
89:
84:
80:
78:
72:
68:
65:
60:
58:
50:
48:
46:
42:
38:
34:
30:
26:
22:
1066:
1062:
1045:
1036:
1026:
1012:
988:
926:
922:
884:
880:
874:
849:
840:
831:
822:
813:
804:
795:
786:
777:
768:
759:
750:
741:
732:
723:
692:
683:
561:
560:
544:Infant colic
527:
526:
479:
478:
446:
445:
429:
428:
402:constipation
373:
372:
301:
300:
263:
262:
259:
256:
252:
243:
213:
204:
195:
187:
148:
145:
130:
126:
122:
111:, using the
106:
92:
87:
85:
81:
76:
73:
69:
61:
54:
36:
20:
18:
551:G6. Infant
496:Levator ani
457:gallbladder
416:/distension
1106:Categories
651:Brian Lacy
599:disorders
589:Aerophagia
473:pancreatic
344:disorders
325:disorders
271:chest pain
140:See also:
553:dyschezia
296:dysphagia
96:pediatric
25:diagnosis
1083:16678568
943:27144617
901:27147121
664:See also
498:syndrome
466:disorder
459:disorder
414:bloating
408:diarrhea
342:vomiting
323:Belching
201:Rome III
170:Altered
164:Altered
210:Rome IV
192:Rome II
103:Process
51:History
1081:
985:"Home"
941:
899:
383:(IBS)
338:Nausea
290:Globus
283:Reflux
184:Rome I
619:H2c.
602:H2a.
587:H1d.
518:F3b.
504:F2c.
494:F2a.
361:(CHS)
357:B3c.
354:(CVS)
350:B3b.
240:base.
1079:PMID
939:PMID
897:PMID
595:H2.
542:G4.
485:F1.
422:C6.
379:C1.
366:B4.
340:and
336:B3.
321:B2.
307:B1.
288:A4.
281:A3.
275:A2.
39:, a
19:The
1071:doi
1067:130
931:doi
927:150
889:doi
885:150
1108::
1077:.
1065:.
1061:.
997:^
987:.
974:^
951:^
937:.
925:.
921:.
909:^
895:.
883:.
858:^
701:^
90:.
79:.
1085:.
1073::
1020:.
991:.
945:.
933::
903:.
891::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.